Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
View: Text | PDF
Research Article AIDS/HIV Immunology Infectious disease

T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal

  • Text
  • PDF
Abstract

Early antiretroviral therapy (ART) limits viral reservoir establishment in infants but also constrains virus-specific immunity required to clear reactivated cells. In the early ART context, we evaluated whether combining adeno-associated virus serotype 9–vectored (AAV9-vectored) eCD4-IgG1 with pharmacological latency reversal using the second mitochondria-derived activator of caspases (SMAC) mimetic AZD5582 could promote reservoir reduction and control in SIV-infected infant macaques. AAV9 delivery achieved sustained eCD4-IgG1 expression, and AZD5582 induced on-ART viremia, but the combination did not reduce intact SIV proviral DNA relative to controls. Partial postintervention control of viremia during analytical treatment interruption (ATI) occurred in 2 of 6 infants receiving AAV9-eCD4-IgG1 plus AZD5582 with restricted reservoir expansion during recrudescence at week 13. Intact reservoir size during ATI correlated inversely with on-ART viremia during AZD5582 treatment. Animals were classified as controllers or non-controllers. Controllers did not show increased eCD4-IgG1 expression nor increased on-ART viremia during AZD5582 treatment but harbored less pre-ART intact SIV DNA in PBMCs than non-controllers. Controllers also exhibited higher frequencies and greater polyfunctionality of virus-specific CD8+ T cells prior to ATI. These findings suggest immune control of reservoir size and post-ART viral dynamics in early-treated infants and that AAV9-eCD4-IgG1 plus AZD5582 increases the likelihood of post-ART viral control.

Authors

Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi

×

Figure 4

Virological rebound and reservoir dynamics after analytical treatment interruption.

Options: View larger image (or click on image) Download as PowerPoint
Virological rebound and reservoir dynamics after analytical treatment in...
(A and B) Longitudinal plasma SIV RNA after ATI in intervention (A) and control (B) animals, plotted on a log10 scale. Gray lines indicate individual animal trajectories; the 2 intervention animals exhibiting partial postintervention viral control are shown in red in A. Solid blue and orange lines indicate group means for intervention and control animals, respectively, with corresponding shaded areas indicating ± SEM. The dotted horizontal line denotes the assay limit of detection (60 copies/mL). (C) Per-animal geometric mean plasma SIV RNA across the ATI period (weeks 0–20), grouped by treatment and controller status: controllers (red), intervention non-controllers (filled blue), and control non-controllers (open orange). Groups were compared using a 2-tailed Mann-Whitney U test. (D) Kaplan-Meier estimates of time to detectable viral rebound, defined as plasma SIV RNA >60 copies/mL. Groups were compared using the log-rank (Mantel-Cox) test; the hazard ratio for intervention relative to control was estimated using the observed-minus-expected method. (E) Per-animal geometric mean plasma SIV RNA across the ATI period, grouped by controller status: controllers (red) and non-controllers (filled black, intervention; open black, control). (F) Intact SIV proviral DNA in PBMCs at week 13 after ATI, expressed as intact proviral DNA assay copies per 106 PBMCs. (G) Fold-change in intact SIV proviral DNA from pre-ATI baseline to week 13 after ATI; the dotted horizontal line indicates no change (fold change = 1). In A–D, n = 6 animals per group; in E–G, n = 2 controllers and n = 10 non-controllers. Horizontal lines indicate group geometric means in C and E and group medians in F and G.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts